Metadata record for the article: Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial

<b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related article: “Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial”. The related study examined metformin impact on metabolic factors in non-diabetic subjects to determine whether this impact varies by baseline BMI, insulin and rs11212617 SNP in CCTG MA.32, a double-blind placebo controlled randomised adjuvant breast cancer (BC) trial. Type of data: single-nucleotide polymorphism (SNP); clinical data Subject of data: <i>Homo sapiens</i> Sample size: 2915 Population characteristics: See Table 1 of the related article Trial registration number: http://clinicaltrials.gov/show/NCT01101438 <b>Data access</b> The SNP data are openly available as part of this <i>figshare </i>metadata record in the file ‘MA32_snp_data.csv’. The primary efficacy analysis will be available from the Canadian Cancer Trials Group (Kingston, Ontario) after the results of the analysis have been published. These data will be uploaded to the NCI data archive website: https://nctn-data-archive.nci.nih.gov/view-trials and will be searchable via NCT trial number NCT01101438. As of April 2021, the group is working towards this publication. Further details can be requested from the corresponding author. The clinical data are not publicly available for the following reason: data contain information that could compromise research participant privacy. <b>Corresponding author(s) for this study</b> Dr. Pamela J. Goodwin, Mount Sinai Hospital, 1085-600 University Avenue, Toronto, Ontario M5G 1X4. Tel: [phone]. Fax: [phone]. Email: [e-mail]. <br> <b>Study approval </b> The study protocol was approved by institutional review boards of participating institutions, including the NCI (US) Central Institutional Review Board and Mount Sinai Hospital (Ontario Cancer Research Ethics Board).